NEW YORK – Qiagen said on Wednesday that it has forged a collaboration with BioNTech to develop and commercialize a tissue-based companion diagnostic to identify patients with squamous cell head and neck cancer caused by specific human papillomavirus (HPV) infections, who may be eligible for BioNTech's investigational cancer treatment BNT113.
To read the full story....
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?
Login Now.
Don't have a 360Dx or GenomeWeb account?
Register for Free.